Table 3 Number of cases and prevalence of MetS with 95% CI according to the different MetS definitions, by gender and age group
WHO (1998) | NCEP-ATP III (2004) | IDF (2005) | JIS (2009) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |||
Total | n=5687 | 1007 | 17.7 (16.7-18.7) | 1896 | 33.3 (32.1-34.5) | 2360 | 41.5 (40.2-42.8) | 2448 | 43.0 (41.8-44.3) | |
Male | Total | n=2621 | 588 | 22.4 (20.8-24.0) | 927 | 35.4 (33.6-37.3) | 1195 | 45.6 (43.7-47.5) | 1260 | 48.1 (46.2-50.0) |
Age group | 25-34 | 15 | 4.0 (2.5-6.5) | 54 | 14.5 (11.3-18.4) | 63 | 16.9 (13.4-21.0) | 72 | 19.3 (15.6-23.6) | |
35-44 | 30 | 7.1 (5.0-10.0) | 101 | 24.0 (20.2-28.3) | 130 | 30.9 (26.7-35.4) | 141 | 33.5 (29.1-38.1) | ||
45-54 | 101 | 21.2 (17.8-25.1) | 185 | 38.9 (34.6-43.3) | 233 | 48.9 (44.5-53.4) | 247 | 51.9 (47.4-56.3) | ||
55-64 | 179 | 30.0 (26.5-33.8) | 263 | 44.1 (40.2-48.1) | 333 | 55.9 (51.9-59.8) | 346 | 58.1 (54.0-61.9) | ||
65-74 | 188 | 36.2 (32.2-40.4) | 246 | 47.4 (43.1-51.7) | 313 | 60.3 (56.0-64.4) | 320 | 61.7 (57.4-65.7) | ||
75+ | 75 | 31.8 (26.2-38.0) | 78 | 33.1 (27.4-39.3) | 123 | 52.1 (45.8-58.4) | 134 | 56.8 (50.4-62.9) | ||
Female | Total | n=3066 | 419 | 13.7 (12.5-15.0) | 969 | 31.6 (30.0-33.3) | 1165 | 38.0 (36.3-39.7) | 1188 | 38.7 (37.0-40.5) |
Age group | 25-34 | 4 | 0.9 (0.4-2.3) | 25 | 5.8 (3.9-8.4) | 29 | 6.7 (4.7-9.4) | 31 | 7.1 (5.1-10.0) | |
35-44 | 13 | 2.6 (1.5-4.5) | 64 | 13.0 (10.3-16.2) | 88 | 17.8 (14.7-21.5) | 88 | 17.8 (14.7-21.5) | ||
45-54 | 48 | 8.8 (6.7-11.5) | 150 | 27.5 (23.9-31.4) | 177 | 32.4 (28.6-36.5) | 179 | 32.8 (29.0-36.8) | ||
55-64 | 89 | 14.4 (11.9-17.4) | 239 | 38.7 (35.0-42.6) | 279 | 45.2 (41.3-49.2) | 285 | 46.2 (42.3-50.1) | ||
65-74 | 142 | 23.4 (20.2-26.9) | 289 | 47.6 (43.7-51.6) | 350 | 57.7 (53.7-61.5) | 358 | 59.0 (55.0-62.8) | ||
75+ | 123 | 33.3 (28.7-38.3) | 202 | 54.7 (49.6-59.7) | 242 | 65.6 (60.6-70.2) | 247 | 66.9 (62.0-71.5) | ||